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Abstract
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Introduction—BRCA mutation testing has been used for screening women at high risk of breast
and ovarian cancer and for selecting the best treatment for those with breast cancer. To optimize
the infrastructure and medical resources allocation for genetic testing, it is important to understand
the use of BRCA mutation testing in the U.S. health system.
Methods—This retrospective cohort study included 53,254 adult women with insurance claims
for BRCA mutation testing between 2004 and 2014 from Clinformatics™ Data Mart Database.
Data analysis was performed in 2016. This study assessed trends in the use of BRCA mutation
testing in women with previously diagnosed breast or ovarian cancer and those without (unaffected
women).
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Results—Between 2004 and 2014, of those receiving BRCA testing, the proportion of BRCA
tests performed in unaffected women increased significantly (p<0.001), from 24.3% in 2004 to
61.5% in 2014. An increase in the proportion of BRCA tests used in unaffected women was found
in each characteristic subgroup. In 2014, most subgroups had a proportion surpassing 50%, except
for those aged 51–65 years and those without a family history of breast cancer. There was a much
lower proportion those aged 20–40 years among tested women with previously diagnosed breast or
ovarian cancer than in unaffected women (17.6% vs 41.7%, p<0.001).
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Conclusions—During the past decade, the role of BRCA testing has gradually shifted from
being used primarily in cancer patients to being used in unaffected women in the U.S.

INTRODUCTION

Author Manuscript

The discovery of BRCA1 and BRCA2 mutations in breast and ovarian cancer–susceptible
women in 1994 and 19951,2 opened up opportunities for individualized preventive cancer
care in high-risk women.3,4 About 5%–10% of breast cancer cases and 10%–18% of ovarian
cancer cases are attributable to germline BRCA mutations.5–8 Tests for mutations in BRCA
genes can identify high-risk individuals, which can then lead to lifesaving preventive care
through prophylactic treatments.4,9 BRCA mutation testing has been recommended by the
U.S. Preventive Services Task Force (USPSTF) since 2005 for women whose family history
demonstrates an increased risk for BRCA-related cancers.10 However, BRCA testing has not
been well utilized among U.S. women and the majority of at-risk women do not get referrals
for genetic counseling or testing.11–14 It is estimated that only 30% of living breast cancer
patients with a BRCA mutation and 10% of asymptomatic BRCA mutation carriers have
been identified in the U.S.14 This lack of referrals results in missed opportunities for cancer
prevention.
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In addition to underuse among patients at risk, BRCA testing is often used among women in
whom the testing may not be indicated by practice guidelines.15–18 It is estimated that
approximately 60%–80% of patients referred for genetic counseling and testing do not meet
the referral requirement based on family history.11,19 To optimize the infrastructure and
medical resources allocated for genetic testing, it is important to understand the current use
of BRCA mutation testing in the U.S. health system. This study assessed trends in the use of
BRCA mutation testing in cancer patients and unaffected women among U.S. adult women
(aged 20–65 years) from 2004 to 2014.

METHODS
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Administrative data from Clinformatics™ Data Mart Database (OptumInsight, Eden Prairie,
MN) was used. This data set contains de-identified insurance claim records from >56 million
Americans who were insured at least once between 2000 and 2014. The administrative
claims records are from a private health insurance provider with plans available in all 50
U.S. states and the District of Columbia. The database includes information on a population
that is roughly representative of the working U.S. population.20 Overall, 73% of the
enrollees were non-Hispanic whites, which is higher than that of the general U.S.
population. Median household income of the enrollees was $62,500 annually.21 From this
data set, a retrospective cohort was generated including women who received BRCA testing
between 2004 and 2014. This study did not include women who received BRCA tests before
2004, because there were not many (one in 2002 and 176 in 2003 among women of any
age). This study included adult women aged 20–65 years, as BRCA-related cancers
generally have an adult onset22 and U.S. adults aged >65 years are eligible for Medicare and
may not be captured in this data set. There were 16.4 million adult women (aged 20–65
years) covered in this data set between 2004 and 2014. Of 57,011 women aged 20–65 years
who received BRCA mutation test between 2004 and 2014, a total of 3,757 women who had
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<3 months of continuous enrollment in health insurance coverage prior to BRCA testing
were excluded. Women with <3 months of enrollment prior to BRCA testing were excluded
because this study wanted to determine whether they had a recent diagnosis of breast or
ovarian cancer. A total of 53,254 women were included in the final analyses. This study
evaluated whether those women had previously diagnosed breast or ovarian cancer within 3
months prior to the date of BRCA testing. This study was exempt from full board review by
the IRB at University of Texas Medical Branch.
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Current Procedural Terminology codes and Healthcare Common Procedure Coding System
for the BRCA mutation test (81211-81217, S3818-S3820, S3822, and S3823) were used to
identify women who received BRCA testing. Cases of previously diagnosed breast cancer
were identified by the ICD-9 code V10.3 for personal history of malignant neoplasm of
breast, 174.x for malignant neoplasm of female breast, and 233.0 for carcinoma in situ of
breast within 3 months before BRCA testing. Cases of previously diagnosed ovarian cancer
were identified by ICD-9 code V10.43 for personal history of malignant neoplasm of ovary
and 183.0 for malignant neoplasm of ovary within 3 months before BRCA testing. Family
history of breast cancer was identified by ICD-9 code V16.3 (family history of malignant
neoplasm of the breast). Family history of ovarian cancer was identified by ICD-9 code
V16.41 (family history of malignant neoplasm of the ovary).
Women’s age at BRCA testing was categorized into three groups: 20–40 years, 41–50 years,
and 51–65 years, for the consideration of different incidences of breast cancer among those
age groups and definition of early-onset of breast cancer (age ≤40 years3, or age ≤50
years 23,24). Regions of residence were divided according to the U.S. Census Regions
(South, Northeast, Midwest, and West).
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Statistical Analysis
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This study assessed the linear trends in the proportions of unaffected women among those
who received BRCA testing from 2004 to 2014. The differences in characteristics between
women with and without previously diagnosed breast or ovarian cancer were assessed by
chi-square test. Age was analyzed both as a continuous variable and a categorical variable.
Multivariable logistic regression models were used to assess the trends. When the linear
trends were assessed, the predictor in the model was the year of BRCA testing, and the
dependent variable was unaffected woman or cancer patient. Variables that were controlled
for included age and region of residence. AOR for the annual change (1-year increase in the
time of BRCA testing) was calculated. The interaction terms of age group, region of
residence, previously diagnosed breast or ovarian cancer, and family history of breast or
ovarian cancer with the year of BRCA testing were assessed in the multivariate logistic
model. Statistical analyses were conducted using SAS, version 9.4. A two-sided p-value
<0.05 was considered statistically significant.

RESULTS
Characteristics of the participants are presented in Table 1. The absolute number of BRCA
tests increased among both women with and without previously diagnosed breast or ovarian
cancer (Table 2). Among 53,254 women who received BRCA testing, 29.3% were aged 20–
Am J Prev Med. Author manuscript; available in PMC 2018 June 01.
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40 years and 36.9% were aged 41–50 years. There was a significant difference in the age
distribution between cancer patients and unaffected women (χ2=3880.9, p<0.001) (Table 1).
The proportion of women aged 20–40 years was much higher in unaffected women than in
cancer patients (41.7% vs 17.6%) and the mean age was significantly lower in unaffected
women (43.0 years, SD=10.3) than in cancer patients (48.6 years; SD=8.6; t-value for testing
the difference, 67.9; p<0.001). The largest proportion (48.7%) of the sample resided in the
South. A high proportion of women had previously diagnosed breast cancer (47.8%), 4.4%
had previously diagnosed ovarian cancer, and 51.3% had been diagnosed with either; 40,900
(76.8%) had a family history of breast cancer, 15,061 (28.3%) had a family history of
ovarian cancer, 44,815 (84.2%) had a family history of breast or ovarian cancer, and 11,146
(20.9%) had a family history of breast and ovarian cancer. Of those receiving BRCA testing,
the proportion of women with a family history of breast or ovarian cancer decreased among
both unaffected women and among cancer patients from 2004 to 2014 (Table 2). The
decrease was greater in cancer patients (from 73.5% to 63.0%) than in unaffected women
(from 98.4% to 95.2%).
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Among women who received BRCA testing, the proportion of unaffected women increased
greatly from 2004 to 2014 (Figure 1A). In 2004, only 24.3% of BRCA tests were performed
among unaffected women. Since 2006, the proportion of BRCA tests conducted in
unaffected women increased sharply (for linear trend from 2004 to 2006, the AOR for the
annual change was 1.05, 95% CI=0.95, 1.14, p=0.29; for linear trend from 2006 to 2014, the
AOR for the annual change was 1.19, 95% CI=1.18, 1.20, p<0.001), with the proportion
surpassing 50% in 2012 (50.3%). In 2014, a total of 61.5% of BRCA tests were performed
in unaffected women. The AOR for the annual change from 2004 to 2014 was 1.19 (95%
CI=1.18, 1.20, p<0.001) (Table 3). For each subsequent year of BRCA testing, the tested
subject had a 19% increase in the odds of being an unaffected woman as opposed to a cancer
patient.
Significant interactions between the year of BRCA testing and age, region, and family
history of breast or ovarian cancer were found (p<0.001 for all tests of the interaction terms).
The proportion of BRCA tests used in unaffected women increased greatly in each
characteristic subgroup, after adjusting for age and region of residence (Figure 1B–D). In
2014, most subgroups had a proportion surpassing 50%, except for those aged 51–65 years
and those without a family history of breast cancer. In 2014, among young women (aged 20–
40 years), >80% of BRCA tests were performed in women without previously diagnosed
breast or ovarian cancer. The AOR for the annual change in the proportion of unaffected
women among those who received BRCA testing stratified by age, region, and family
history are presented in Table 3.
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DISCUSSION
In this study, a gradual shift was observed in the role of BRCA testing from being used
primarily in cancer patients to being used in unaffected women from 2004 to 2014. The
proportion of tests performed in unaffected women shifted from one in four in 2004 to
greater than 60% in 2014. BRCA testing in patients with early-onset breast or ovarian cancer
can identify those with high-risk mutations, in whom specific treatment options may be
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needed.4,25–28 Another important role of BRCA testing is to identify high-risk mutation
carriers before they develop breast or ovarian cancer, so they may start cancer screening at
an early age, receive intensified screening (MRI/mammogram), and undergo prophylactic
treatments (chemotherapy and prophylactic surgery) for the prevention and early detection
of breast and ovarian cancer.4,9,16,29,30 However, the majority of at-risk women do not get
referral for genetic counseling and testing.12–14 Among 220,000 BRCA mutation carriers in
the U.S., it is estimated that more than 90% have not been identified.14 The 2008 Genetic
Information Nondiscrimination Act may allay the fears of genetic information misuse and
boost the utilization of genetic testing. Practice guidelines by the National Comprehensive
Cancer Network and USPSTF have continuously loosened the clinical testing criteria for
genetic counseling and BRCA mutation testing,10,24,31–33 which may also be partly
responsible for the increase in the overall utilization of BRCA testing in unaffected women.
Since 2011, the Affordable Care Act has mandated coverage for preventive services
recommended by USPSTF, including referring eligible women for genetic counseling and
BRCA testing.34 Moreover, the 2013 Supreme Court ruling against Myriad Genetics’ patent
claims of BRCA mutation test and subsequent availability of the testing in other clinical labs
have greatly reduced the cost of the test.35–37 Additional efforts are still needed to extend
coverage of BRCA testing among women at risk of hereditary breast or ovarian cancer. The
shifted role of BRCA testing was observed across age groups, region of residence, and status
of family history of breast or ovarian cancer. Significant interactions between the year of
BRCA testing and age, region, and family history of breast or ovarian cancer indicated that
there were differences in the magnitude of the annual change across those population
subgroups. Over the past decade, widespread direct to consumer marketing for genetic tests
has raised consumers’ interest in BRCA testing, and increased women’s self-referrals and
referrals by their physicians to genetic services even when they are at low-risk for
mutations.38–43 Further studies are needed to assess the factors associated with BRCA test
use in unaffected women and in cancer patients among population subgroups, in order to
maximize the likelihood of identifying mutation carriers so that they may choose proper risk
management plans or cancer treatment options accordingly.
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In addition, population-based screening for BRCA1 and BRCA2 mutations in Ashkenazi
Jewish women and the general population has been proposed and evaluated.35,36,44,45 The
estimated prevalence of potentially harmful BRCA mutations is 0.2%–0.3% among the
general population,6,46 but tenfold higher (2.1%) in Ashkenazi Jewish women,47–49 and
about 30-fold higher (6.0%) in women with cancer onset before age 40 years.3,50,51 Owing
to the vast differences in the prevalence of potentially harmful BRCA mutations within
population subgroups and the high-cost of BRCA testing, currently USPSTF and the
National Comprehensive Cancer Network only recommend screening for individuals with
increased risk for potentially harmful BRCA mutations based on personal history and family
history.31,52 It is worth mentioning that in three relatively large studies in Canada, Israel, and
England, more than one half of Ashkenazi mutation carriers do not qualify for genetic
testing based on family history.53 Most young women with breast cancer do not have a
family history of breast or ovarian cancer or Ashkenazi Jewish ancestry, and will not be
eligible to undergo BRCA mutation testing before a cancer diagnosis.54–56 In clinical
practice, BRCA testing is not performed only among women at risk for harmful mutations
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based on family history and personal history of cancer. This may be due to inadequate
knowledge57,58 among physicians about indications for the test, understanding the
limitations of personal/family history based testing criteria and awareness of new clinical
evidences among physicians,53–56 changing testing guidelines,10,24,31–33 patient anxiety and
patient request, given massive and intensive marketing campaigns targeting the public and
the clinicians by Myriad Genetics and others.59 A survey conducted in 2007 assessed the
level of awareness and utilization of BRCA testing among U.S. primary care physicians and
found that only 19% of physicians correctly identified family history patterns and 45%
chose at least one low-risk scenario as an indication for BRCA testing.57 Another vignettebased survey of 3,000 U.S. primary care providers found that about 30% of U.S. physicians
would consider referring women not at high risk for genetic counseling and testing.58 In
addition, most of patients referred for genetic counseling and testing do not meet the referral
requirements based on family history.11,19 Nevertheless, with low-cost genetic testing ($200
or $300, roughly the price of a three-dimensional mammogram) available,37 practical
guidelines may further loosen the testing criteria, and more unaffected individuals and
cancer patients will choose to receive the test even when they have to pay out of pocket.60,61
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Limitations

Author Manuscript
Author Manuscript

The main strength of this study was the use of administrative data from a large national
sample to reliably assess trends and patterns in use of BRCA testing in the U.S. health
system. This study also had several limitations. First, the analysis was based on medical
claims and administrative information from a database of privately insured individuals, and
may not be applicable to women covered by public health insurance (e.g., Medicaid) or who
were uninsured. The largest proportion (48.7%) of the sample resided in the South,
compared with 45.9% of adult women (aged 20–65 years) in the overall database who
resided in the South, higher than that in the U.S. general population. Additionally, there is a
possibility that family history and personal history of previously diagnosed breast or ovarian
cancer were not documented within 3 months prior to BRCA testing. Some women may be
misclassified as not having previously been diagnosed with breast or ovarian cancer. In
general, there are many initiatives to improve documentation in the past 10 years.62 The 3month window in the current study captured most of the personal history of breast or ovarian
cancer, compared with the personal history from the BRCA test request form in the
American BRCA Outcomes and Utilization of Testing (ABOUT) Study.60 The ABOUT
Study found that 46.7% of 11,159 female Aetna commercial health plan members whose
clinicians ordered BRCA testing between December 2011 and December 2012 reported a
personal history of breast or ovarian cancer,60 compared with 49.7% in women who received
BRCA testing in 2012 in the current study. Physicians do not always take or update the
family history,63 and there is a lack of completeness in documented family history.64 The
data set also lacked a detailed and comprehensive family history of breast or ovarian cancer
to assess whether those women met testing criteria.16,52 The ICD-9 codes for family history
of breast or ovarian cancer did not capture the number of family members or their
relationship to the subject. In addition, this data set did not have sociodemographic
information of the enrollees, so disparities in the use of BRCA testing across different races/
ethnicities and socioeconomic groups could not be assessed.
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CONCLUSIONS
The role of BRCA testing in the U.S. has gradually shifted over the past decade from being
used primarily in cancer patients to being used in unaffected women. Advancement in
genetic sequencing technologies and the Supreme Court ruling against the patenting of
genes may further reduce testing cost, provide opportunities for practical guidelines to
loosen testing criteria, and allow more individuals to benefit from this test.
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Figure 1. Trends in proportion of unaffected women among women who received BRCA tests,
from 2004 to 2014

Author Manuscript

Notes: A. All women. B. By age groups. C. By region of Residence. D. By family history of
breast or ovarian cancer. Data are plotted as proportion (%). The whisker represents the 95%
CI. P-values for the tests of the interaction terms between the year of BRCA testing and age,
region, and family history of breast or ovarian cancer were all <0.001.
20–40 y: 20–40 years of age.
Year: the year when BRCA testing was performed.
Unaffected women: women who did not have previously diagnosed breast or ovarian cancer.
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Region of residence: South included Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas, Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina,
South Carolina, Virginia, and West Virginia; Northeast included Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania; Midwest included
Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota; West included Arizona, Colorado, Idaho, Montana, Nevada, New Mexico,
Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.

g

Age: mean age in unaffected women was 43.0 years, SD 10.3, and mean age in cancer patients was 48.6 years, SD 8.6.

f

p-value: the p-value of the aforementioned χ2 test.
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AORs for the Annual Change in the Proportion of Unaffected Women Among Those who Received BRCA
Testing, Overall and Stratified by Participant Characteristics (N=53,254)
Characteristics

AOR (95% CI)a

p-value

Overall

1.19 (1.18–1.20)b

<0.001

20–40 years

1.25 (1.23–1.26)c

<0.001

41–50 years

1.18 (1.17–1.19)c

<0.001

51–65 years

1.15 (1.14–1.17)c

<0.001

Age

Region of residence

Author Manuscript

South

1.20 (1.19–1.21)d

<0.001

Northeast

1.11 (1.09–1.13)d

<0.001
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1.19 (1.17–1.21)d
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Family history of breast cancer or ovarian cancer
No

1.44 (1.37–1.51)b

<0.001

Yes

1.21 (1.20–1.22)b

<0.001

a

AOR for the annual (1-year increase in the time of BRCA testing) change in the proportion of unaffected women among those who received
BRCA testing.

b

Adjusted for age and region of residence.

c
Adjusted for region of residence.
d

Adjusted for age.
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